ClinicalTrials.gg

Program

CYP11A1 Inhibitor ACE-232

Its studies are mostly in Prostatic Neoplasms, led by Acerand Therapeutics (Hong Kong).

Furthest: phase 1, since Jan 19, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acerand Therapeutics (Hong Kong)11 open or runningphase 1since Jan 19, 2025Jan 19, 2025Dec 31, 2028phase 1 · NCT06801236

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2025First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06801236 · 88 planned · United States, China

Ahead

  1. Dec 31, 2028Primary completion: phase 1 study in Prostatic NeoplasmsNCT06801236

TargetBeta

CYP11A1 →read by rule
“An orally bioavailable inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1; P450 11A1), ”NCIt, by rule

Other programs on CYP11A1

ProgramCompanyFurthest phaseStudies
opevesostatMerckphase 313

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06801236Prostatic Neoplasms · United States, China1RecruitingDec 31, 202888

How it is read

Names in the registry

  • “ACE-232 tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.